Zevra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) was the target of some unusual options trading activity on Thursday. Stock traders bought 9,057 call options on the stock. This is an increase of 602% compared to the average volume of 1,291 call options.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ZVRA shares. HC Wainwright began coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a “buy” rating and a $26.00 price target for the company. JMP Securities decreased their price objective on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Zacks Research lowered shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Thursday, July 10th. Finally, Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Zevra Therapeutics has an average rating of “Moderate Buy” and an average price target of $24.00.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode bought 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 19th. The stock was bought at an average cost of $9.16 per share, for a total transaction of $45,800.00. Following the completion of the transaction, the director directly owned 45,000 shares of the company’s stock, valued at approximately $412,200. This trade represents a 12.50% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Woodline Partners LP grew its stake in shares of Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock valued at $34,571,000 after buying an additional 476,032 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares during the period. Rubric Capital Management LP lifted its position in shares of Zevra Therapeutics by 60.8% during the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after purchasing an additional 740,584 shares in the last quarter. AIGH Capital Management LLC boosted its stake in shares of Zevra Therapeutics by 82.4% in the first quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock valued at $10,771,000 after purchasing an additional 649,495 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Zevra Therapeutics by 0.8% in the second quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company’s stock valued at $10,948,000 after purchasing an additional 9,275 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Performance

Shares of Zevra Therapeutics stock opened at $9.52 on Friday. The firm has a market cap of $534.36 million, a PE ratio of -45.33 and a beta of 1.56. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The business’s fifty day simple moving average is $9.69 and its 200-day simple moving average is $8.92.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.